Abcellera Biologics Inc ABCL

$12.70 +0.05 (0.40%)

Valuation

Market cap
3,878,629,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
PE ratio
0.00
Forward PE
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
3,383,800
Avg volume
6,838,356
Day's range
$12.29 – $12.93
Shares out
306,611,000
Stochastic %K
79%
Beta
1.32
Analysts
Strong Sell
Price target
$16.67

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

snowPOW Sep 26, 6:49 PM
$ABCL is not mentioned, this is a discussion about testosterone and menopause. I think that's relevant to this ticker. https://www.cbc.ca/news/health/menopause-testosterone-treatment-9.7358977
0 replies
Merlintrader Sep 26, 9:45 AM
AI and new medicines: what turns a designed candidate into value? $ABCL, $ABSI, $RXRX, $SDGR https://www.merlintrader.com/ai-drug-discovery-evidence-rights-abcl-absi-rxrx-sdgr/
0 replies
erpy Sep 25, 9:40 PM
$ABCL https://www.zacks.com/stock/news/2993825/abcl-stock-surges-121-in-3-months-heres-what-you-need-to-know?cid=CS-STOCKTWITS-HL-analyst_blog|price_surge_/_plunge-2993825&adid=SYND_STOCKTWITS_HEADLINE_ANALYSTBLOG_284_2993825
0 replies
Stocktradesmoon Sep 25, 7:48 PM
$ABCL
0 replies
Stocktradesmoon Sep 25, 7:04 PM
$ABCL Last Chance 12.80’ss!! $13 Next! Largest 2026 IMS Menopause Convention Conference Next Week…we are Presenting the 12 Week Data 📊 for the EXPLOSIVE 🧨 Phase II RESULTS!!! Boom!!!! 💥 🤯 People are getting in Right NOW…Chart is PRIMED for a move $15.89-17’sss!!! So many More will be joining US after hours and buying it UP!! I wouldn’t Miss this OPPORTUNITY!!! I’m READY!!
0 replies
Stocktradesmoon Sep 25, 6:51 PM
$ABCL $13’sss next!
0 replies
Stocktradesmoon Sep 25, 6:21 PM
$ABCL 👏 Your Right! I can’t WAIT! I’m so EXCITED for the World to Learn about $ABCL Millions of People and Institutions will soon Discover what $ABCL is all About!!.. and will Watch the Results for themselves as they Present the 12 WEEK Data 📊 for an already an EXPLOSIVE 🧨 Phase II RESULTS!!! 😮 🤯 🚀 🚀 $17-20’sss next week!!
1 replies
erpy Sep 25, 6:11 PM
$ABCL Grab your shares before any fomo. Fomo isnt the time to add. Get a position your comfortable with jmho. Good luck to all. Added a few times today!!
0 replies